In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
Latest article
Not PLA‑ying dead: Bioplastic skulls replace gory antler mounts
In Utah, Bucks N Bull Skulls is using bioplastic polylactic acid filament to 3-D print animal skulls for mounting antlers – an alternative that...
Funding flatlines: Meatable closes up shop
In the Netherlands, cultivated meat pioneer Meatable has failed to secure sufficient funding and is winding down operations. The company had been operating a...
“Sound” investment: Biobased acoustic panel maker Aisti receives €20 million EIB loan
In Finland, sustainable acoustics products firm Aisti has received a €20 million (US$23.4 million) loan from the European Investment Bank to scale production of...